Generic Sarafem Availability
SARAFEM (fluoxetine hydrochloride - capsule;oral)
Manufacturer: ELI LILLY AND CO
Approval date: July 6, 2000
Strength(s): EQ 10MG BASE [RLD], EQ 20MG BASE [RLD]
SARAFEM (fluoxetine hydrochloride - tablet;oral)
Approval date: May 19, 2006
Strength(s): EQ 10MG BASE [RLD] [AB1], EQ 15MG BASE [RLD] [AB1], EQ 20MG BASE [RLD] [AB1]
Has a generic version of Sarafem been approved?
Yes. The following products are equivalent to Sarafem:
Manufacturer: TORRENT PHARMS LTD
Approval date: October 21, 2016
Strength(s): EQ 10MG BASE [AB1], EQ 20MG BASE [AB1]
Manufacturer: TEVA PHARMS USA
Approval date: February 3, 2014
Strength(s): EQ 10MG BASE [AB1], EQ 15MG BASE [AB1], EQ 20MG BASE [AB1]
Note: No generic formulation of the following product is available.
- fluoxetine hydrochloride - capsule;oral
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Sarafem. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQs.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Sarafem (fluoxetine)
- Sarafem Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 21 Reviews
- Drug class: selective serotonin reuptake inhibitors
- FDA Alerts (8)
Related treatment guides
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AB||Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (i.e., AB1, AB2, AB3, etc.). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.|